Current detection and quantification method for gluten to support the gluten-free claim: an insight about elisa method

N. S. Deora
{"title":"Current detection and quantification method for gluten to support the gluten-free claim: an insight about elisa method","authors":"N. S. Deora","doi":"10.15406/JNHFE.2018.08.00259","DOIUrl":null,"url":null,"abstract":"Celiac disease (CD) is an enteropathy mediated by immunological mechanisms triggered by the interaction of gluten with the intestinal mucosa in affected individuals [1]. The consequences of this condition are the intestinal extensions leading to malabsorption and malnutrition [2]. The only currently effective health strategy for affected consumers is to avoid glutencontaining products, and such the food must be labelled clearly. However, despite unanimously accepted Codex definitions by all member jurisdictions, the national implementation of equivalent laws displays significant variations. With reference to CD and in support of the gluten-free statement, regulatory enforcement, as well as manufacturers’ quality controls are typically centered and rely on analytical results. The market for the gluten free is expanding and needs to develop and further improve the detection methods for gluten is of paramount importance. Currently, commercially available antibody-based assays are designed to detect gluten to verify and support gluten-free claims in the context of CD. However, these assays are not developed for the purpose of detecting gluten-containing cereals in the context of food allergies. The other wheat allergens which are water soluble like globulins and albumins are also targeted by commercial ELISA kits. Secondly, there are no thresholds established for food allergens, and the lower limit of Quantification (LOQs) of commercial assays for gluten may not be suitable for testing of allergen. Additionally, there is a gap between gluten free definition and food allergen labeling regulation. For example, gluten-free definitions state the reporting unit as mg gluten/kg product, which is used by the kits. However, food allergen labeling regulations mandate the common name of the cereal to be labeled. Commercial assays report only gluten with no conversion factor from gluten to cereal available [3]. Moreover, because currently available kits indistinguishably detect gluten from wheat, rye, and barley, it is not possible to identify the source of cereal. However, it is to be noted that not all food allergen regulations mandate the labeling of gluten-containing cereals as is the case in Europe and Australia. The United States requires only wheat, and Canada requires wheat and triticale. Japan does, not have gluten-free regulations, but requiring the labeling of the presence of wheat and buckwheat as allergens on the food label. In Japan, they use commercial kits to determine and quantify the presence of soluble wheat protein. It is reasonable to state that, Japanese kits are used to determine the presence of wheat in the context of food allergies in accordance with local regulation food allergies.","PeriodicalId":331573,"journal":{"name":"Journal of Nutritional Health & Food Engineering","volume":"71 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nutritional Health & Food Engineering","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/JNHFE.2018.08.00259","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Celiac disease (CD) is an enteropathy mediated by immunological mechanisms triggered by the interaction of gluten with the intestinal mucosa in affected individuals [1]. The consequences of this condition are the intestinal extensions leading to malabsorption and malnutrition [2]. The only currently effective health strategy for affected consumers is to avoid glutencontaining products, and such the food must be labelled clearly. However, despite unanimously accepted Codex definitions by all member jurisdictions, the national implementation of equivalent laws displays significant variations. With reference to CD and in support of the gluten-free statement, regulatory enforcement, as well as manufacturers’ quality controls are typically centered and rely on analytical results. The market for the gluten free is expanding and needs to develop and further improve the detection methods for gluten is of paramount importance. Currently, commercially available antibody-based assays are designed to detect gluten to verify and support gluten-free claims in the context of CD. However, these assays are not developed for the purpose of detecting gluten-containing cereals in the context of food allergies. The other wheat allergens which are water soluble like globulins and albumins are also targeted by commercial ELISA kits. Secondly, there are no thresholds established for food allergens, and the lower limit of Quantification (LOQs) of commercial assays for gluten may not be suitable for testing of allergen. Additionally, there is a gap between gluten free definition and food allergen labeling regulation. For example, gluten-free definitions state the reporting unit as mg gluten/kg product, which is used by the kits. However, food allergen labeling regulations mandate the common name of the cereal to be labeled. Commercial assays report only gluten with no conversion factor from gluten to cereal available [3]. Moreover, because currently available kits indistinguishably detect gluten from wheat, rye, and barley, it is not possible to identify the source of cereal. However, it is to be noted that not all food allergen regulations mandate the labeling of gluten-containing cereals as is the case in Europe and Australia. The United States requires only wheat, and Canada requires wheat and triticale. Japan does, not have gluten-free regulations, but requiring the labeling of the presence of wheat and buckwheat as allergens on the food label. In Japan, they use commercial kits to determine and quantify the presence of soluble wheat protein. It is reasonable to state that, Japanese kits are used to determine the presence of wheat in the context of food allergies in accordance with local regulation food allergies.
支持无谷蛋白声明的现有谷蛋白检测和定量方法:关于elisa法的见解
乳糜泻(Celiac disease, CD)是一种由免疫机制介导的肠病,是由患者的麸质与肠黏膜相互作用引发的[1]。这种情况的后果是肠道扩张导致吸收不良和营养不良[2]。对于受影响的消费者而言,目前唯一有效的健康策略是避免使用含谷蛋白的产品,这类食品必须清晰地贴上标签。然而,尽管所有成员司法管辖区一致接受了食典委的定义,但各国对同等法律的实施却存在显著差异。关于乳糜泻,为了支持无谷蛋白声明,监管执法以及制造商的质量控制通常以分析结果为中心并依赖于分析结果。无谷蛋白食品的市场在不断扩大,开发和进一步完善无谷蛋白食品的检测方法至关重要。目前,商业上可获得的基于抗体的检测旨在检测谷蛋白,以验证和支持乳糜泻背景下的无谷蛋白声明。然而,这些检测并不是为了检测食物过敏背景下的含谷蛋白谷物而开发的。其他水溶性的小麦过敏原如球蛋白和白蛋白也是商业ELISA试剂盒的目标。其次,食品过敏原没有设定阈值,面筋商业测定法的定量下限(loq)可能不适合过敏原的检测。此外,无麸质定义和食品过敏原标签法规之间存在差距。例如,无麸质定义将报告单位定为mg麸质/kg产品,这是试剂盒使用的单位。然而,食品过敏原标签法规要求在标签上标注谷物的通用名称。商业检测只报告谷蛋白,没有从谷蛋白到谷物的转换因子[3]。此外,由于目前可用的试剂盒无法区分小麦、黑麦和大麦中的麸质,因此无法确定谷物的来源。然而,值得注意的是,并非所有的食品过敏原法规都像欧洲和澳大利亚那样强制要求在含麸质的谷物上贴标签。美国只需要小麦,加拿大需要小麦和小黑麦。日本没有无谷蛋白法规,但要求在食品标签上标明小麦和荞麦是否属于过敏原。在日本,他们使用商业试剂盒来确定和量化可溶性小麦蛋白的存在。可以合理说明的是,日本检测试剂盒是根据当地有关食物过敏的规定,在食物过敏的情况下测定小麦是否存在。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信